Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Study ID
NCT04873141
Status
Completed

Conditions

  • Covid-19 Pneumonia
  • Cytokine Release Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.

Key Dates

First listed
May 5, 2021
Start date
Apr 28, 2020
Status verified
May 2021
Primary completion
Jun 22, 2020
Completion
Jun 22, 2020

Study Design

Enrollment
24 participants (actual)

Arms

  • Arm: Case Group
    All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.

Primary Outcome Measure

Mortality Rate [ Time Frame: 28 days ]

Related Studies